Clinical Trials
Enrolling Trials
31-40 of 112
for
"cancer"
CIRB-Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)
Brandt, Jon
Leukemia
Leukemia
Adult, Child
This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
DTL-CIRB-A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Brandt, Jon
Neuroblastoma
Child
This phase III trial tests how well adding dinutuximab to induction chemotherapy along with standard of care surgery radiation and stem cell transplantation works for treating children with newly diagnosed high risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. Chemotherapy drugs such as cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, dexrazoxane, doxorubicin, temozolomide, irinotecan and isotretinoin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. During induction, chemotherapy and surgery are used to kill and remove as much tumor as possible. During consolidation, very high doses of chemotherapy are given to kill any remaining cancer cells. This chemotherapy also destroys healthy bone marrow, where blood cells are made. A stem cell transplant is a procedure that helps the body make new healthy blood cells to replace the blood cells that may have been harmed by the cancer and/or chemotherapy. Radiation therapy is also given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of induction.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
DTL - pCIRB; A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Brandt, Jon
Lymphoma
Child
This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Treatment for PMBCL involves chemotherapy combined with an immunotherapy called rituximab. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving nivolumab with chemo-immunotherapy may help treat patients with PMBCL.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Brandt, Jon
Mutations
Mutations
Adult, Child
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, Renal Tumors Classification, Biology, and Banking Study
Brandt, Jon
Biology
Child
This phase III trial compares the effect of vincristine, dactinomycin, and cyclophosphamide to vincristine and dactinomycin in treating patients with very low risk or low risk fusion negative rhabdomyosarcoma and examines the use of molecular risk stratification in the treatment of rhabdomyosarcoma. Patients with certain tumor mutations will be treated with longer therapy. Giving standard chemotherapy drugs for a longer time may work better in treating patients with rhabdomyosarcoma with mutations. Chemotherapy drugs, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues of the body.
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
pCIRB, A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma.
Brandt, Jon
Rhabdomyosarcoma/Soft Tissue Sarcoma
Child
This phase III trial compares the effect of vincristine, dactinomycin, and cyclophosphamide to vincristine and dactinomycin in treating patients with very low risk or low risk fusion negative rhabdomyosarcoma and examines the use of molecular risk stratification in the treatment of rhabdomyosarcoma. Patients with certain tumor mutations will be treated with longer therapy. Giving standard chemotherapy drugs for a longer time may work better in treating patients with rhabdomyosarcoma with mutations. Chemotherapy drugs, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues of the body.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
WCG, ICH - DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
Sharma, Rohit
Melanoma
Adult
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
ICH, CIRB, Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Ly, Bevan
Breast
Adult
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB, Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Onitilo, Adedayo A
Cancer Symptom Management
Cancer Symptom Management
Adult, Child
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.
Marshfield Medical Center - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9601 TOWNLINE RD
MINOCQUA, WI 54548
MMC - River Region at Stevens Point
MMC - Weston
3501 CRANBERRY BLVD
WESTON, WI 54476
CIRB, Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Onitilo, Adedayo A
Cancer Prevention
Adult
FORTE is a colorectal cancer prevention study looking to determine how often participants who have had 1-2 small benign polyps removed during colonoscopy from their colon otherwise known as adenomatous polyps or adenomas should have repeat surveillance colonoscopies. The primary goal of FORTE is to compare the colorectal cancer rates between the two study groups (repeat colonoscopy at 5 and 10 years versus repeat colonoscopy at 10 years) to see if the rates are equivalent. If they are equivalent, then people in the future would likely be recommended to only undergo a 10-year exam and the 5-year exam may not be necessary. Participants will be asked to donate blood and stool samples and will be followed annually.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449